The IFReC Kishimoto Foundation

The Kishimoto Foundation was established in 2008 in honor of Dr. Tadamitsu Kishimoto, who, during the 1980s and 90s, elucidated the function of interleukin-6 (IL6), a key molecule for stimulating immune responses. He later developed the anti-IL6 receptor-based therapy tocilizumab to treat immune disorders such as Castleman's disease, rheumatoid arthritis and juvenile idiopathic arthritis. The Foundation supports research and innovation in biomedicine at Osaka University, where Dr. Kishimoto was formerly the President.

The WPI Immunology Frontier Research Center (IFReC), Osaka University, has launched a fellowship program supported by the Kishimoto Foundation, for researchers in various fields of immunology. The program is designed to support overseas researchers in order to promote and develop immunological research and international exchange at IFReC.

For more information, click here.